Related references
Note: Only part of the references are listed.Renal brush border strategy: A developing procedure to reduce renal radioactivity levels of radiolabeled polypeptides
Yasushi Arano
NUCLEAR MEDICINE AND BIOLOGY (2021)
Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis
Ravikumar Shah et al.
CLINICAL ENDOCRINOLOGY (2021)
Modulation of the Pharmacokinetics of a Radioligand Targeting Carbonic Anhydrase-IX with Albumin-Binding Moieties
Shimpei Iikuni et al.
MOLECULAR PHARMACEUTICS (2021)
Radiotheranostics Using a Novel 225Ac-Labeled Radioligand with Improved Pharmacokinetics Targeting Prostate-Specific Membrane Antigen
Shimpei Iikuni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent
Kazuma Nakashima et al.
CHEMICAL COMMUNICATIONS (2021)
Exendin-4 analogs in insulinoma theranostics
Tom J. P. Jansen et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2019)
Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation
Mingru Zhang et al.
BIOCONJUGATE CHEMISTRY (2019)
Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting
Simon A. M. Kaeppeli et al.
MOLECULAR PHARMACEUTICS (2019)
Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies
Joseph Lau et al.
BIOCONJUGATE CHEMISTRY (2019)
Radioligand Therapy of Prostate Cancer with a Long-Lasting Prostate-Specific Membrane Antigen Targeting Agent 90Y-DOTA-EB-MCG
Zhantong Wang et al.
BIOCONJUGATE CHEMISTRY (2018)
Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy
Christoph A. Umbricht et al.
MOLECULAR PHARMACEUTICS (2018)
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors
Zhantong Wang et al.
BIOCONJUGATE CHEMISTRY (2018)
Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study
Kwadwo Antwi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies
Hsiou-Ting Kuo et al.
MOLECULAR PHARMACEUTICS (2018)
Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study
Yaping Luo et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET
Andreas Bauman et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Characterisation of radioiodinated flavonoid derivatives for SPECT imaging of cerebral prion deposits
Takeshi Fuchigami et al.
SCIENTIFIC REPORTS (2015)
DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid-Targeted Lu-177-Radionuclide Tumor Therapy in Mice
Cristina Mueller et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances
Tetsuhide Ito et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
Shawn M. Hillier et al.
CANCER RESEARCH (2009)
Secular Trends in the Presentation and Management of Functioning Insulinoma at the Mayo Clinic, 1987-2007
Kimberly A. Placzkowski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric bombesin analogues for multimodality tumor imaging and therapy
Keelara Abiraj et al.
CHEMICAL COMMUNICATIONS (2008)
Reducing renal uptake of radiolabeled peptides using albumin fragments
Erik Vegt et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma
Andreas Wicki et al.
CLINICAL CANCER RESEARCH (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Characterization of proteinuria and tubular protein uptake in a new model of oral L-lysine administration in rats
K Thelle et al.
KIDNEY INTERNATIONAL (2006)
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs
L Simonsen et al.
DIABETOLOGIA (2006)
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
EJ Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Albumin binding as a general strategy for improving the pharmacokinetics of proteins
MS Dennis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
